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CXCR4 is a 7-transmembrane G-protein chemokine receptor that allows for migration of hematopoietic cells from the bone
marrow to the peripheral lymph nodes. Research has shown CXCR4 to be implicated in the invasion and metastasis of several
cancers, including carcinoma of the breast. CXCL12 is the ligand for CXCR4 and is highly expressed in areas common for breast
cancer metastasis, including the axillary lymph nodes. Axillary lymph nodes positive for breast carcinoma have been an important
component of breast cancer diagnosis, treatment, and subsequent research. The goal of this paper is to analyze the literature that
has explained the pathways from CXCR4 expression to breast cancer metastasis of the lymph nodes and the prognostic and/or
predictive implications of lymph node metastases in the presence of elevated CXCR4.
1.Introduction
Lymph nodes of the axilla have been studied in the context of
breast cancer since before Halsted published his study pro-
posingthatthislymphaticdrainagewasapathwayformetas-
tasis and recommending axillary node dissection (AND) [1].
The understanding of breast cancer metastasis has changed
greatly over the past century. Sentinel lymph node biopsies
(SNB) allowed for detection of smaller micrometastases that
have previously gone undetected. Understanding the true
beneﬁt for the use of AND with SNB has been a topic of
discussion, and a recent trial has suggested that there is no
advantage of AND in patients with a negative SNB [2]. In
contrast, an earlier report slightly favored disease-free sur-
vival and overall survival in AND patients over just SNB
(albeit with a limited number of patients) [3]. This comes 10
years after data was published describing a 30-year followup
of internal mammary node dissections that did not improve
survival of breast cancer patients [4]. The questioning of
the therapeutic value of axillary node dissection in certain
patient populations has allowed for further exploration of
the prognostic and/or predictive value of these organs. A
clearer picture of the molecular mechanisms of lymph node
metastases is the next step to designing optimal therapeutic
options and to create new treatment modalities.
One such molecular avenue is chemokine receptor
CXCR4, a seven transmembrane G protein-coupled receptor
that has been implicated in the invasion and metastasis of
several cancers, including breast. Over 20 chemokine recep-
tors have been identiﬁed and are keys to pathways that in-
clude the body’s response to allergy, inﬂammation, and me-
tastasis. Although a great deal of research into CXCR4 began
by focusing on its role in HIV entry of CD4+ cells [5, 6],
M¨ ulleretal.discoveredthatCXCR4wasintegralforthepath-
way that activates actin polymerization and pseudopodia
formation in breast cancer cells [7]. CXC chemokine ligand-
12 (CXCL12), also known as stromal-derived factor-1 (SDF-
1), is the ligand for CXCR4. M¨ uller’s lab noted that CXCL12
was found in high concentrations at sites that were common
for metastasis, such as brain and bone. For this paper, we will
only use the term CXCL12.
A litany of studies have emerged in the last ﬁve years
examiningCXCR4andaxillarylymphnodes,coveringmulti-
pleapproachesofhowCXCR4inthesettingofaxillarylymph2 International Journal of Breast Cancer
nodes can impact our understanding of breast cancer. This
review aims to coalesce several papers across the spectrum
of this research to tie together molecular pathways and
illustrate emerging trends to help direct future research into
CXCR4 as a prognostic and/or predictive marker for breast
cancer.
2.Biology ofCXCR4and
LymphNode Metastasis
CXCR4 was initially discovered as HUMSTR [8]a n dL E S T R
[9] and later renamed according to proper nomenclature for
chemokine receptors. The action of CXCR4 leads to intra-
cellular signaling cascades that are involved with traﬃcking,
migration, and proliferation. One major site of involvement
is in hematopoiesis, due to its expression on CD34+ cells
in bone marrow. Evidence points to its role in maintaining
hematopoietic progenitor cells [10]. It is also a factor in
immune system cells, including monocytes, dendritic cells,
NK cells, and na¨ ı v eTc e l l s .T h ep r o p o s e dr o l eo fC X C R 4i st o
helptheimmunesystemmigratetositesofinjury,butM¨ uller
et al. have shown it to be actively involved in metastasis at
sites expressing its ligand, CXCL12, playing an important
role in the tumor microenvironment [7].
The ligand CXCL12 has been further characterized by
Crump et al. to understand how it binds to CXCR4 [11].
Their in vitro studies revealed CXCL12 to have two binding
sites for CXCR4. The RFFESH loop on CXCL12 initially
bindswithanN-terminalsegmentofCXCR4.Thisallowsfor
access to a second receptor site of CXCR4 for the N-terminal
region of CXCL12 to bind, altering the conformation of the
CXCR4 transmembrane helices and activating the G-protein
signal pathway. That signal is able to aﬀect multiple targets,
includingERK1/2,MAPK,JNK,andAKTpaths,withtheend
result being events such as chemotaxis, pseudopodia forma-
tion, and actin polymeriazation [12–14].
In addition to its role within the immune and hemato-
poietic systems, CXCR4 has also been implicated as a com-
ponent in angiogenesis [15, 16]. A well-known component
of angiogenesis in tumor cells is vascular endothelial growth
factor (VEGF), which has also shown to be prognostic in
colonandgastriccancer[17,18].CXCR4hasbeenconnected
with VEGF, as increased stimulation of CXCR4 leads to
increased secretion of VEGF and ultimately angiogenesis
and metastasis [19–21]. To achieve metastatic potential,
the tumor cells must migrate away from the primary site.
Tumor cells must break through the protective extracellular
matrix (EM) in order to reach the lymph or blood vessels.
Matrix metalloproteinases (MMPs) are essential for this
component of invasion, as they cause degradation of EM.
One MMP specifically, MMP-9, has been linked to VEGF
[22].
In addition to CXCR4/CXCL12, VEGF, and MMPs, HIF-
1α has also shown to be a component of this pathway. HIF-
1α is a dimeric transcription factor that increases in deoxy-
genated environments. Hypoxic conditions are known to
promote angiogenesis and have been connected to increased
HIF-1α and VEGF [23]. Additionally, CXCR4 has proven
to be increased in hypoxic conditions [24]. The connection
between hypoxia, CXCR4, and invasive cancer has been out-
lined by Sun et al. in a series of experiments that illustrated
the connection and molecular pathway between hypoxia in
chondrosarcoma, CXCR4 expression, and matrix metallo-
proteinases. Hypoxic conditions that produced higher levels
of HIF-1α were observed to subsequently increase CXCR4
expression through the binding of HIF-1α to the promoter
region of CXCR4. Subsequent CXCR4/CXCL12 signaling via
the ERK pathway increased MMP expression and activity
[25]. While this pathway was worked out on cell lines for
chondrosarcoma, HIF-1α increases in hypoxic conditions
have also been shown to upregulate CXCR4 in carcinoma of
the breast [26].
Another component that has been linked to CXCR4 up-
regulation is nitric oxide (NO). While already known to
induce VEGF [27], Nakamura et al. have been able to show
that NO also induces the lymphangiogenic factor VEGF-C
[28]. In more recent work from their laboratory, MDA-MB-
231 cell lines incubated with NO revealed an increased cyto-
plasmic CXCR4 staining. Cytoplasmic CXCR4 significantly
correlated with nitrotyrosine levels, lymph node metastasis,
and distant metastasis [29].
The location of CXCR4 staining is a common feature
in several of the papers to be described in this review. The
CXCR4 receptor resides on the membranes of cells, but IHC
has helped reveal patterns between cytosolic and nuclear ex-
pression of CXCR4. Tarasova et al. [30]o b s e r v e de n d o c y -
tosis of membranous CXCR4 receptors in the presence of
CXCL12. Salvucci et al. [31] noted that cytoplasmic CXCR4
was seen more often in ductal carcinoma in situ (DCIS) pa-
tientswhencomparedtonuclearstaining.Thatgroupspecu-
lated that cytoplasmic CXCR4 staining could be indicative of
“active CXCR4 functioning,” as if the cancer cells are ready to
leave the primary tumor. While nuclear staining of CXCR4
has been tested and observed in many studies, the reasons
behind its diﬀerence in expression from cytoplasmic CXCR4
has not yet been uncovered.
A viable pathway illustrating the role of CXCR4 in
breast carcinoma migration from the primary site does not
explain how these cells are guided to axillary lymph nodes.
Studies have shown CXCL12 to be expressed on the luminal
surface of high endothelial venules (HEVs) in peripheral
lymphnodes[32].HEVsarepostcapillaryvenulesthatenable
circulating lymphocytes to enter lymph nodes. CXCL12 is a
factor in hematopoietic precursors moving from the bone
marrow into the circulation, and ultimately to peripheral
tissues [10]. Blades et al. designed a study that showed
that CXCL12-induced migration mediated by CXCR4 con-
trolled the migration of human peripheral blood lympho-
cytes into lymph nodes previously transplanted into SCID
mice [33]. Liu et al. performed a series of experiments ex-
hibiting CXCL12 concentrations to be signiﬁcantly higher
in lymph node metastases compared to their primary breast
cancer tumor [34]. The location-based chemotaxic ability
of CXCL12, combined with its aﬀect on CXCR4-expressed
cells, creates a microenvironment for tumor migration
(Figure 1).International Journal of Breast Cancer 3
Table 1: CXCR4 and lymph node metastasis in recent studies.
Study Findings P value
Hao et al. [35]
↑CXCR4 with ↑TNM stage <0.037
↑CXCR4 with +lymph node mets <0.001
↑CXCR4/VEGF w/+LN mets 0.007
↑CXCR4/MMP-9 w/+LN mets <0.001
Kang et al. [36]
↑CXCR4 in +LN tumors over −LN tumors 0.03
↑CXCR w/OS or distant mets-not observed in this data —
Parker et al. [37] ↑CXCR4 w/+LN had worse 5yr OS 0.02
Cabioglu et al. [38] ↑CXCR4 w/+LN 0.113
Su et al. [39] ↑CXCR4 (cytoplasmic) with +LN mets 0.0325
CXCR4: CXC chemokine receptor 4, LN mets: lymph node metastases, MMP-9: matrix metalloproteinase-9, VEGF: vascular endothelial growth factor.
CXCR4
↑CXCL12
Primary tumor Peripheral lymph node
Chemotaxis-
based migration
CXCL12
Pseudopodia
formation, actin
polymerization
VEGF MMP HIF-1α
Figure 1:DepictionofaprimarytumoroverexpressingCXCR4and
the basic factors associated with its migration to peripheral lymph
node sites. Increased concentrations of CXCL12 have been noted at
lymph node metastasis sites when compared to the primary tumor.
3.CXCR4LevelsandAssociationto
Lymph Node Status
With knowledge of the molecular connections between
CXCR4,VEGF,andMMPs,Haoetal.askediftherewasaany
association between these three components of metastasis
and lymph node status in breast cancer patients [35]. The
location of CXCR4 staining was studied in breast cancer
tissue samples, benign tissue samples that were adjacent to
tumor tissue, and atypical hyperplasia samples. CXCR4 was
found in both the cytoplasm and the nucleus of mammary
cells. Benign tissue adjacent to tumor lesions exhibited weak
cytoplasmic CXCR4 staining. The malignant samples had
significantly higher rates of CXCR4, VEGF, and MMP-9
compared to the benign and nontumor (hyperplastic) sam-
ples (P<0.01). Looking at clinicopathologic factors, statis-
tical signiﬁcance was found upon analyzing either CXCR4
or VEGF with the tumor’s TNM stage. In addition, all three
markers had signiﬁcant association with advanced histologic
grade.
When analyzing the primary tumors, increased expres-
sion levels of CXCR4, VEGF, and MMP-9 associated with the
p r e s e n c eo fl y m p hn o d ep o s i t i v eb r e a s tc a n c e r( P<0.001).
Results showed a lymph node metastasis rate of 79% with
tumors expressing high levels of both CXCR4 and VEGF
compared with a 45% rate when only one of these factors
is high (P = 0.007). In contrast, a 6% rate was observed (P<
0.001) when neither factor was highly expressed. Any com-
bination of two of the three markers, each highly expressed,
had a signiﬁcant increase in lymph node metastases. Finally,
thisstudyshowedthathighCXCR4expressionwaspositively
associated with increased VEGF and MMP-9 expression
(Table 1).
Kang et al. have shown that high CXCL12 expression in
breast cancer tissue is linked to nodal and distant spread of
breast cancer cells, as well as a link to overall survival [36]. To
follow up this study, this group focused on CXCR4’s relation
to metastasis and survival [40], as opposed to its ligand.
Using immunohistochemistry, CXCR4 was detected in both
breast cancer cell lines as well as normal mammary tissue.
It was shown that node-positive tumors had a signiﬁcantly
increased expression of CXCR4 when compared to node-
negative tumors. CXCR4 expression was higher in the me-
tastatic cohort compared to the nonmetastatic group, but
signiﬁcance was not achieved when looking at a relationship
between elevated CXCR4 and presence of distant metastases
or overall survival (Table 1).
Parker et al. evaluated a cohort of 185 node-positive
breast cancer patients and found that CXCR4 overexpression
level in primary tumors independently predicted a poor
outcome for these patients [37]. The 5-year overall survival
for patients with low and high CXCR4 overexpression was
69% and 57%, respectively, (P = 0.02, Table 1). These results
suggest that even within this high risk group (i.e., node
positive patients), CXCR4 can be employed to identify those
patientswhohaveamoreaggressivediseasecourseandthere-
fore can be targeted for more intensive and/or novel therapy.
Not all studies have successfully concluded CXCR4 to
definitely predict outcome. Cabioglu et al. studied CXCR4
as a predictive marker for lymph node metastasis along
with CCR7 [38], another chemokine receptor that has been
shown to be expressed in breast cancer cells [7]. The group
attempted to reduce confounding eﬀectsthatcanaccompany
T2-4 lesions by limiting this study to only T1 lesions. Dif-
ferences in CXCR4 and CCR7 staining location were tested,
with node-positive tumors showing higher cytoplasmic
CCR7 and HER2 staining than node-negative tumors. There
was an increased rate of CXCR4 in node-positive patients
(11.2% versus 5.1%), but this diﬀerence was not signiﬁcant
(Table 1). The authors theorized that CCR7 is associated4 International Journal of Breast Cancer
with lymph node metastasis, while CXCR4 expression aids
in the reliability of CCR7 as a biomarker. When Liu et al.
investigated the relationship between CXCR4 and CCR7,
they found in their data set that CXCR4 and CCR7 each sig-
nificantly associated with lymph node metastasis. A lower
overall survival was noted via the Kaplan-Meier survival
analysis of both CXCR4 and CCR 7 overexpression [34].
The diﬀerence between nuclear and cytoplasmic CXCR4
staining has emerged as an important factor in CXCR4’s
prognostic/predictive ability [41]. Su et al. examined the ex-
pression location of CXCR4 in breast cancer cells and tested
for associations in marker staining and metastasis [39]. The
study was designed to compare 3 groups: (1) patients with
sentinel and nonsentinel lymph node metastasis, (2) patients
with only sentinel lymph node metastasis, and (3) patients
with neither sentinel or nonsentinel metastasis. Combining
groups 2 and 3 together (they chose for sole sentinel node
positivity to be equivalent to no metastasis) revealed that
high cytoplasmic CXCR4 expression was associated with
axillary lymph node status (P = 0.0325, Table 1). Their
data did not show any other correlations with cytoplasmic
or nuclear CXCR4 staining and any other clinicopathological
factor. Essentially, these results show that elevated cytoplas-
mic CXCR4 are indicative of spread beyond the sentinel
lymph node.
4. AutocrineversusParacrineCXCL12
The knowledge that stromal cells express CXCL12 opens
the theory that location, along with concentration, can be
important in predicting outcome. Kang et al. found that
when adding CXCL12 to the cell line MDA-MB-231, there
was increased migration and invasion ability. That study
showed an inverse relationship between CXCL12 expression
levels and disease-free and overall survival in breast cancer
patients. Increased CXCL12 caused an increased incidence of
recurrence and lymph node metastasis [36].
Mirisola et al. conducted a series of experiments to help
explaintheautocrine/paracrineeﬀectofCXCL12[42].When
analyzing 100 breast cancer samples, IHC studies showed
that groups highly expressing CXCL12 tended to be smaller
tumors and lymph node negative (P = 0.04, P = 0.002).
Also noted was a signiﬁcant association between DFS and
the expression pattern of CXCL12, speciﬁcally expression at
the tumor periphery (P = 0.002). CXCR4 expression in this
data was not signiﬁcant for DFS or OS. Tumors expressing
CXCL12hadabetterclinicaloutcomethanthosethatlostthe
chemokine. The authors’ explanation is that when CXCL12
is produced by the tumor, the autocrine function of CXCL12
renders the tumor insensitive to its eﬀects and cancels any
metastatic potential. Tumor growth via the ERK pathways
and VEGF are still in play, but metastatic potential is lost.
Thus, it can be inferred that tumors not overly expressing
CXCL12 show a paracrine eﬀect and maintain metastatic
potential.
The idea that CXCL12 can inhibit the eﬀect of CXCR4
was further explored by Shim et al. [26]. First, they were
able to produce results that showed breast cancer lymph
node metastases were overexpressed at a lower rate than they
were at the primary tumor. Next, they moved to explain
how increased CXCL12 concentrations can aﬀect CXCR4,
a ﬁnding previously noted in Liu et al. [34]. After creating
an “expression score” to quantify CXCR4 expression in their
breast cancer and lymph node specimens, this group was
able to show that primary breast cancer specimens exhibited
a higher score than lymph node metastases (P<0.001).
Two immunostaining patterns were noticed. 58% of primary
tumor samples had membranous staining of CXCR4 pre-
dominate, versus 80% of lymph node metastases having cy-
toplasmic staining predominate. In the reviewed papers Hao
et al. [35], Su et al. [39], Yasuoka et al. [29], and Liu et al.
[34] each of these observed cytoplasmic staining to associate
with lymph node metastasis.
This group studied CXCL12 mRNA levels of 10 primary
breast cancer tumors along with their matching lymph node
metastases and observed CXCL12 levels to be higher in
lymph node tumors than the primary breast tumor (P<
0.001). For a control, the MDA-MB-231 cell line was exam-
ined. CXCR4 staining was observed to be predominantly
membranous in this line. However, after incubation with
CXCL12 for 30 minutes, CXCR4 expression was found in
the cytoplasm. Furthering this experiment, MDA-MB-231
cells were exposed to 100 and 200ng/mL concentrations of
CXCL12for48hours.CXCR4wasthenmeasuredbyWestern
blot, and expression as found to be signiﬁcantly decreased.
This group then tested chloroquine, known to inhibit
proteolysis of lysosomes, with the MDA-MB-231 cell line
and found CXCR4 expression returned while still in the
presence of high concentrations of CXCL12. This suggests
that high CXCL12 concentrations cause cellular degradation
of CXCR4 receptors.
5.AlternateResearch PathwaysandQuestions
It has been widely accepted that CXCL12 is the exclusive
ligand of CXCR4. Burns et al. have altered this belief with
a study documenting the ability of CXCL12 to bind to
CXCR7 (RDC1, CCX CJR2), a novel receptor that was ﬁrst
characterized as a chemokine receptor in this paper [43].
They were able to show that CXCL12 binds to CXCR7 by
transfecting a cell line lacking CXCR4 and CXCR7 with the
RDC1 gene, resulting in high-aﬃnity CXCL12 binding even
in the presence of the CXCR4 inhibitor, AMD3100. In the
following experiments, Burns et al. introduced CXCR7 into
breast cancer cell line MDA MB435s and documented an
increase in cell growth and increased adhesion to human
umbilical vein endothelial cells. This lab’s continued investi-
gationofCXCR7hassinceshownthatitpromotesbreastand
lungcancerinmurinemodels[44].Additionally,CXCR7was
undetectable or at low levels in normal human breast tissue
frommammoplasties,butwasclearlydetectedinover30%of
humanbreastcancerspecimens.Itwasalsodetectablein97%
of blood vessel specimens from human breast cancer, versus
being “undetectable or nearly undetectable” in normal blood
vessels from normal breast tissue.
Searching for new biomarkers is more complex than
locating factors with changed expressions from their benignInternational Journal of Breast Cancer 5
baseline, according to Ransohoff and Gourlay [45]. They
state that several forms of bias might account for the fact that
while many targets have been identiﬁed as biomarkers, very
few have had “clinical value.” This bias possibly occurs before
a specimen arrives to a laboratory in the form of collection
and storage. One example cited details a group investigating
prostate cancer that questioned whether differences in stor-
agetimebetweenthecancerandnoncancerspecimengroups
aﬀected the end results [46]. Ransohoﬀ and Gourlay’s assess-
ment of bias concludes that subject selection is of utmost
importance—“inequality of specimen groups” is a major
source of bias in experiments where the outcomes are obser-
vations, not laboratory results. They believe that improving
the attention given to specimens, both in selection and man-
agement once acquired, might improve the quality of results
in biomarker identiﬁcation research.
6. Conclusion
CXCR4 is an important factor in breast cancer metastasis.
The molecular pathway for its action, along with associated
factors, is continuing to be broken down piece by piece. A
myriad of components appear to play important roles in the
overexpression of CXCR4, from NO and VEGF to MMPs
and HIF-1α.D i ﬀerences have been noted in CXCR4 between
primary tumors and lymph node metastases, speciﬁcally in
the amount of overexpression: CXCR4 has been found to
be more highly overexpressed at the primary tumor than at
lymph node metastases. Repeated in many papers is the fact
that cytoplasmic CXCR4 staining is noted to associate with
lymph node metastasis while nuclear CXCR4 staining has
not had signiﬁcant results. Studies into the responsibilities of
CXCR4’s ligand, CXCL12, have revealed increased concen-
tration of the ligand at distant sites, speciﬁcally the lymph
nodes. Another important issue with CXCL12 is the idea
that tumors that produce high amounts of the chemokine
eﬀectively downregulate CXCR4 receptors, while tumors
without high CXCL12 expression maintain a prometastatic
ability. The role of CXCR7 further clouds the picture when
attempting to understand what is more important to target
while grasping CXCL12’s eﬀect on both CXCR7 and CXCR4
in the same tumor microenvironment.
CXCR4 has been identiﬁed as a receptor for CXCL12,
changes in expression location patterns of CXCR4 have been
described, and positive associations with disease outcome
have been derived. New discoveries concerning CXCR7,
paracrine/autocrine CXCL12 eﬀects, and more careful plan-
ning in discovery and examination of biomarkers will help
shape the future directions of this research. Possibilities exist
for collaboration and shared information; the results of
which could alter the current understanding and treatment
of breast cancer, both local and systemic.
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